Sign up
Pharma Capital

Summit Therapeutics sees a bright future for its antibiotics programmes

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM), spoke to Proactive's Andrew Scott following the disappointing results from the mid-stage study of their Duchenne muscular dystrophy drug.

Edwards says one of the key focuses going forward is Ridinilazole, Summit’s lead candidate, which is due to enter phase III trials in the first quarter of 2019.

Using their Discuva drug discovery platform, the company's also identified two possible compounds for gonorrhoea – a sexually transmitted infection which affects an estimated 78mln people every year.

 

View full SUMM profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.